| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| SABR COMET 3 | CTRIAL-IE 19-21 | Oligometastatic disease who have one controlled primary solid tumour and 1-3 current metastatic lesions, and a maximum of 8 lifetime metastatic lesions |
The purpose of the study is to assess the impact of Stereotactic Ablative Radiotherapy (SABR), compared to standard of care (SOC) treatment, on overall survival, oncologic outcomes, and quality of life in patients with 1-3 current metastatic lesions. |
DSSG Group: Basket (multiple types)
MK7339-002 / LYNK-002
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK7339-002 / LYNK-002 | CTRIAL-IE 19-27 | Multiple types of cancer |
This study will evaluate the efficacy and safety of olaparib monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic). |
Add-Asprin
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Add-Asprin | 16-19 | Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured. |
The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours. |